Executive Profiles

Nuvation CEO David Hung discusses his leadership style, success stories for building camaraderie, and his inspiration for joining the pharma and biotech industry.

The two executives discuss joining Persica Pharmaceuticals and how they’re driving the company forward with non-opioid pain medication.

Fresh off the HBA's Honorable Mentor award, Rick Winningham, CEO of Theravance Biopharma, reflects on a career defined by cultivating the cultures driving the science.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

BeOne Medicines’ John Oyler on building an oncology pharma power from a disruptive idea — and playing the long game on speed, science and scale.

Tris Pharma’s founder and CEO discusses his company’s history and how’s he’s adjusted his strategies over the decades.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

Inside Consano Bio’s bet on first-in-class nerve repair—and what it takes to lead an early-stage biotech through uncertainty.

From lessons in risk-taking—and building “from zero”—to career-defining pivots, Leonard Mazur, CEO of Citius Pharmaceuticals, reflects on 50-plus years in pharma.

Inside Brent Saunders’ return run as CEO of Bausch + Lomb—and setting the storied eye care pharma on a bold path of reinvention.

Cencora CEO Bob Mauch discusses the lessons learned during his first year at the helm—and tackling a complex future for pharma distribution.

Artax Biopharma’s CEO Rob Armstrong explains recent shifts in autoimmune R&D before discussing his leadership style.

Kitamura discusses implementing cost management initiatives and positioning the company to weather near-term challenges.

The founder of InflaRX discusses lessons learned during the COVID-19 pandemic and how they’re being applied in a post-pandemic world.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

The Boehringer Ingelheim leader discusses his leadership style and how it impacts his team’s strategy.

The EMD Serono president discusses his new role and goals for the company.

The Medipost CEO discusses developing treatments for knee osteoarthritis and other conditions.

RheumaGen’s CEO discusses the company’s work editing HLA alleles.

The ADDF’s CFO discusses the areas that foundation is raising money for and how its reacting to the current economic environment.

Jim Weiss, founder and chairman of Real Chemistry, and the 2025 HBA Honorable Mentor, discusses the foundation and journey behind his lifelong advocacy for mentorship—and, cliché or not, the lasting power of “you get what you give.”

Reshema Kemps-Polanco, executive VP and chief commercial officer, Novartis US, and the 2025 Healthcare Businesswomen’s Association Woman of the Year, uses the lessons she learned from her family to bring out the best in her teams.

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and stretching the boundaries in healthcare exploration.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to recapture the heights of old.